Delivery Order 36F79720D0180-36C24921N0300
Award Date 1/12/21
Potential Completion Date 1/21/21
Potential Value $284K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
East Hanover, NJ 07936, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 9 awarded a $283,526.57 delivery order to Novartis Pharmaceuticals Corp. for the provision of CAR T cells (Kymriah injection, suspension) under the Pharmaceuticals and Drugs (FSS-61-IB) GSA Schedule. The delivery order was awarded on November 5, 2020 with a completion date of November 5, 2020. The pricing is firm fixed price and performance will take place in East Hanover, New Jersey. The...
- This federal contract award to Novartis Pharmaceuticals Corporation, doing business as NPS, is for the delivery of Kymriah, a specialized cell therapy cancer treatment, to the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA). The contract is issued as a delivery order against Novartis' existing Federal Supply Schedule (FSS) 61-IB contract for pharmaceuticals and drugs, which has a potential value of $5.4 billion and runs through August 2025. The specific delivery...
- This firm fixed-price delivery order was awarded by the Department of Veterans Affairs Veterans Health Administration to Novartis Pharmaceuticals Corporation, a foreign-owned, for-profit manufacturer, to provide the Kymriah chimeric antigen receptor T-cell therapy to the Nashville VA Medical Center. The order, valued at $283,526.57, was issued against Novartis' Federal Supply Schedule 61-IB contract for pharmaceuticals and drugs, which has a total potential value of $5.4 billion. Kymriah is a...
- This is a delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Novartis Pharmaceuticals Corporation, a foreign-owned, for-profit manufacturer, to provide the chimeric antigen receptor T-cell therapy drug Kymriah. The order, valued at $283,567.92, was placed against Novartis' Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) and has a firm fixed price. The order supports the VA's medical programs and does not have a...
- This federal contract award is for the pharmaceutical product Kymriah (tisagenlecleucel), a chimeric antigen receptor T-cell (CAR-T) therapy, provided by the prime contractor Novartis Pharmaceuticals Corporation. The contract has a ceiling value of $283,555.92 and is a Blanket Purchase Agreement (BPA) call under Novartis' Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The contract was awarded by the Department of Veterans Affairs (VA) and is intended to support...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 9 awarded Novartis Pharmaceuticals Corp., doing business as NPS, a $283,526.57 firm fixed price delivery order for KYMIRAH for patient care at the Nashville VA Medical Center. The delivery order was issued against Novartis' Pharmaceuticals and Drugs Federal Supply Schedule contract, FSS-61-IB, with performance to take place in East Hanover, New Jersey. No set-aside designation was used for...
- This federal contract award is for the delivery of the Kymriah cancer medication to the U.S. Department of Veterans Affairs (VA). The prime contractor is Novartis Pharmaceuticals Corporation, a foreign-owned, for-profit manufacturer of pharmaceutical products. The contract, awarded by the Veterans Integrated Service Network 17 (VISN 17) of the VA, is a Blanket Purchase Agreement (BPA) call against Novartis' Federal Supply Schedule (FSS) contract for pharmaceuticals and drugs (FSS-61-IB). The...
- This federal contract award is for the delivery of Kymriah, a specialized cell therapy cancer treatment, to the Department of Veterans Affairs (VA) through a Blanket Purchase Agreement (BPA) under Novartis Pharmaceuticals Corporation's Federal Supply Schedule (FSS) contract for pharmaceuticals and drugs. The BPA, valued at $283,555.92, was issued by the VA's Veterans Integrated Service Network 9 and has a completion date of January 29, 2021. Novartis Pharmaceuticals Corporation, a foreign-owned,...
- The Department of Veterans Affairs (VA) awarded a $283,526.57 delivery order to Novartis Pharmaceuticals Corporation, doing business as NPS, for emergency drug orders to support the Tennessee Valley Healthcare System (TVHS). This order was placed against Novartis' Federal Supply Schedule (FSS) 61-IB contract for pharmaceuticals and drugs, which has a total potential value of $5.4 billion and runs through August 2025. Novartis, a foreign-owned, for-profit manufacturer, has provided specialized...
- This federal contract award is for the delivery of the radiopharmaceutical PLUVICTO to the Cleveland VA Medical Center (VAMC). The $598,124.52 firm fixed price delivery order was issued against Novartis Pharmaceuticals Corporation's Federal Supply Schedule (FSS) contract for pharmaceuticals and drugs (FSS-61-IB). Novartis, a foreign-owned for-profit manufacturer, has provided specialized cancer therapies like Kymriah to VA networks and facilities under previous orders and agreements. This...